University of Arizona has identified non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

A study revealed that Jun13296, a novel PLpro inhibitor, demonstrates potent antiviral and anti-inflammatory effects in vivo, offering hope for future COVID-19 therapies beyond Paxlovid. Study: Design ...

In a quest to develop new antiviral drugs for COVID-19 and other diseases, a collaboration led by scientists at The Wertheim ...

Interview with Ashish Jha on an investment by the Biden administration in the development of next-generation vaccines and treatments for SARS-CoV-2. 9m 26s Download The development of safe and ...

As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells. In ...

Few studies examine how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests assist or hinder efforts to prevent illness, hospitalisations, or people dying. Due to weak evidence, we’re ...

Approximately 15 to 20 million Americans who have acquired COVID-19 experience persistent symptoms lasting over 3 months (long-COVID). Respiratory symptoms of long-COVID include breathlessness, ...

Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).